Voyager Therapeutics

Voyager Therapeutics Inc. (NASDAQ: VYGR), a U.S.-based biotechnology company, has announced a licensing agreement with Swiss pharmaceutical giant Novartis AG (NYSE: NVS). This agreement provides Novartis with access to a novel capsid from Voyager’s TRACER capsid discovery platform for its gene therapy program targeting an undisclosed rare neurologic disease. Under…